Skip to main content

Table 2 Comparison of key characteristics of the 5 cancer-related identities

From: Diversity of cancer-related identities in long-term prostate cancer survivors after radical prostatectomy

  Someone who has had cancer n = 1468 (%) Patient
n = 882
(%)
Cancer survivor n = 561
(%)
Cancer conqueror n = 364
(%)
Victim
n = 72
(%)
Age at survey (years)**
  ≤ 70 12.7 10.2 7.8 13.2 9.7
  > 70 ≤ 80 49.4 48.2 43.5 45.9 52.8
  > 80 37.9 41.6 48.7 40.9 37.5
Educational level**
 primary, secondary - low 36.3 38.8 46.0 45.1 52.5
 secondary - intermediate 17.9 17.3 15.4 19.0 16.4
 secondary - high 12.5 11.9 12.8 10.2 13.1
 tertiary 33.3 32.0 25.8 25.7 18.0
Partnership
 yes 92.2 91.9 90.7 95.0 91.4
 no 7.8 8.1 9.3 5.0 8.6
Children
 0 12.1 12.8 9.3 9.9 8.5
  ≥ 1 87.9 87.2 90.7 90.1 91.5
Age at surgery (years)
  ≤ 55 13.8 10.0 8.9 13.5 12.5
  > 55 ≤ 65 52.1 51.7 51.7 52.7 55.6
  > 65 34.1 38.3 39.4 33.8 31.9
Time since surgery (years)***
  ≤ 10 5.7 6.8 5.5 5.8 4.2
  > 10 ≤ 15 44.3 42.2 36.0 46.4 43.0
  > 15 ≤ 20 40.7 40.8 41.7 34.9 41.7
  > 20 9.3 10.2 16.8 12.9 11.1
Second primary cancer
 yes 11.7 12.5 15.5 13.7 16.7
 no 88.3 87.5 84.5 86.3 83.3
Family history of PCa
 yes 40.5 35.9 38.2 40.4 33.3
 no 59.5 64.1 61.8 59.6 66.7
Biochemical recurrence during FU****
 yes 31.6 49.1 51.3 39.6 54.1
 no 68.4 50.9 48.7 60.4 45.9
Biochemical recurrence at survey****
 yes 13.7 29.6 21.9 16.8 25.9
 no 86.3 70.4 78.1 83.2 74.1
Discontinued PSA follow-up
 yes 5.3 5.1 6.6 5.5 9.7
 no 94.7 94.9 93.4 94.5 90.3
Ongoing treatment at survey****
 yes 6.2 19.7 18.3 13.0 23.2
 no 93.8 80.3 81.7 87.0 76.8
PHQ-2 (depression screening) ****
 positive screening (≥3) 12.0 15.0 19.7 13.0 39.1
 negative screening (< 3) 88.0 85.0 80.3 87.0 60.9
GAD-2 (anxiety disorder screening) ****
 positive screening (≥3) 9.7 10.2 16.2 8.7 37.3
 negative screening (< 3) 90.3 89.8 83.8 91.3 62.7
Perceived severity of disease****
 low 48.4 50.6 31.1 44.5 18.8
 high 51.6 49.4 68.9 55.5 82.2
Well-being****
 low 32.3 34.5 41.0 24.8 65.2
 high 67.7 65.5 59.0 75.2 34.8
Benefit finding****
 low 59.6 60.6 43.9 48.6 58.6
 high 30.4 39.4 56.1 51.4 41.4
  1. Note: **** p < .0001; *** p < .001; ** p < .01; * p < .05; PCa prostate cancer, FU follow-up, PSA prostate specific antigen, PHQ patient health questionnaire, GAD general anxiety disorder, per. perceived